Showing results (311-320 of 413) with videos related to

Sort By:
Pageof 42
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group StudyAnita L Sabichi, J Jack Lee, Robert J Taylor, et al.
The Journal of Urology|August 5, 2018
Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASSJames T Kearns, Anna V Faino, Jeanette M Schenk, et al.
JAMA Oncology|August 28, 2020
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk StabilityMatthew R Cooperberg, Yingye Zheng, Anna V Faino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
Journal of the National Cancer Institute|September 13, 2007
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention TrialM Scott Lucia, Jonathan I Epstein, Phyllis J Goodman, et al.
JU Open Plus|February 19, 2026
Combining Serum Prostate Health Index With Urinary PCA3 and TMPRSS2:ERG RNA Testing Improves Detection of Clinically Significant Prostate CancerNicholas W Eyrich, Yijian Huang, Yingye Zheng, et al.
European Urology|February 14, 2018
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance OutcomesMatthew R Cooperberg, James D Brooks, Anna V Faino, et al.
Oncotarget|February 22, 2018
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancerDebashis Sahoo, Wei Wei, Heidi Auman, et al.
Carcinogenesis|July 21, 2011
Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention TrialLi Tang, Song Yao, Cathee Till, et al.
The Lancet. Oncology|July 23, 2013
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trialDavid I Quinn, Catherine M Tangen, Maha Hussain, et al.
Pageof 42